Figure 2 | Scientific Reports

Figure 2

From: Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy

Figure 2

Fmr1 KO2 mouse brain BDNF levels recover in assays with use of blarcamesine chronic dosing (twice-daily treatment with blarcamesine 1 mg/kg IP for 14 days). (a) pGSK-3β levels in hippocampus. (N = 10 per group; Fmr1 KO2-Vehicle vs. WT-Vehicle, Fmr1 KO2-Vehicle vs. WT-Treated, Fmr1 KO2-Treated vs. WT-Vehicle, Fmr1 KO2-Treated vs. WT-Treated: All ***p < 0.001; Fmr1 KO2-Vehicle vs. Fmr1 KO2-Treated, WT-Vehicle vs. WT-Treated: Both not significant). (b) Rac1 levels in hippocampus. (N = 10 per group; Fmr1 KO2-Vehicle vs. WT-Vehicle, Fmr1 KO2-Vehicle vs. WT-Treated, Fmr1 KO2-Treated vs. WT-Vehicle, Fmr1 KO2-Treated vs. WT-Treated: All ***p < 0.001; Fmr1 KO2-Vehicle vs. Fmr1 KO2-Treated, WT-Vehicle vs. WT-Treated: Both not significant). (c) BDNF levels in hippocampus. (N = 6 per group; Fmr1 KO2-Vehicle vs. WT-Vehicle, Fmr1 KO2-Vehicle vs. WT-Treated, Fmr1 KO2-Vehicle vs. Fmr1 KO2-Treated: All ***p < 0.001; other comparisons not significant).

Back to article page